Tobi Alegbe

Tobi Alegbe

Auto-generated profile, based on publicly available information

Tobi Alegbe

Wellcome Sanger Institute, Hinxton, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2025 in Nucleic Acids Research
Verified
Journal Article
Open access
PMPedro Madrigal
Pedro Madrigal
ATAnil S Thanki
Anil S Thanki
SFSilvie Fexova
Silvie Fexova
IYIris D Yu
Iris D Yu
ACArsenios Chatzigeorgiou
Arsenios Chatzigeorgiou
CEChristina Ernst
Christina Ernst
Expression Atlas (https://www.ebi.ac.uk/gxa/home) is EMBL-EBI’s comprehensive knowledgebase for gene and protein expression across tissues, cell types, conditions, and multiple species. Since our last update, Expression Atlas has expanded substantially in both content and functionality, now comprising >4500 studies from 67 species, with increased proteomics coverage and updated Genotype-Tissue Expression (GTEx) tissue profiles. The resource also includes hundreds of single-cell RNA-seq experiments spanning 21 species, among them externally analysed community datasets such as Tabula Sapiens and GTEx single-nucleus profiles, allowing exploration of curated atlases while maintaining their original analytical framework. Key methodological advances include a new marker gene analysis module for bulk baseline experiments, alongside workflow updates that improve reproducibility. Expression Atlas data are integrated into EMBL-EBI resources such as Ensembl, UniProt, and Europe PMC and disseminated through collaboration with model organism communities such as FlyBase and Gramene. The resource also supports translational research through the European Diagnostic Transcriptomic Library and integration with the Open Targets platform. Future directions include modernizing analysis pipelines, enhancing programmatic access, and delivering AI-ready data formats, strengthening Expression Atlas as a findable, accessible, interoperable, and reusable (FAIR) community-driven resource for both fundamental and translational discovery.

8 September 2023 in medRxiv
Verified
Preprint
Open access
PDF file
MKMonika Krzak
Monika Krzak
TATobi Alegbe
Tobi Alegbe
DTD Leland Taylor
D Leland Taylor
GJGareth-Rhys Jones
Gareth-Rhys Jones
MGMennatallah Ghouraba
Mennatallah Ghouraba
CDClaire Dawson
Claire Dawson
Summary: Crohn’s disease (CD) is a chronic inflammatory bowel disease exhibiting substantial heterogeneity in clinical presentation and response to therapy. To explore its molecular basis, we developed IBDverse, the largest single-cell RNA sequencing (scRNA-seq) dataset of terminal ileal biopsies, profiling over 1.1 million cells from 111 CD patients and 232 healthy controls. This resource integrates discovery and replication cohorts for robust identification of CD-associated cell types, genes, and pathways. We uncovered epithelial changes marked by interferon-driven MHC-I upregulation, persisting in progenitors after macroscopic inflammation resolution. ITGA4 + macrophages were identified as key inflammatory drivers, showing enriched JAK/STAT signaling and cytokine expression (IL-6, IL-12, IL-23). Heritability analysis linked inflammatory monocytes and macrophages to CD susceptibility, implicating resident and recruited immune cells in pathogenesis. These findings establish a comprehensive cellular and molecular framework for CD, offering new insights into disease mechanisms and therapeutic opportunities.

3 June 2026 in Nature
Verified
Journal Article
Open access
TATobi Alegbe
Tobi Alegbe
BHBradley T. Harris
Bradley T. Harris
LFLaura Fachal
Laura Fachal
LRLucia Ramirez-Navarro
Lucia Ramirez-Navarro
MTMarcus Tutert
Marcus Tutert
CACarl A. Anderson
Carl A. Anderson
Most genetic variants associated with complex diseases lie in non-coding regions 1 , complicating efforts to identify effector genes and relevant cell types. Here we map cis -expression quantitative trait loci (eQTLs) across 2.2 million single cells using intestinal biopsies and blood from 421 individuals, including 125 with inflammatory bowel disease (IBD). Cell-type-level eQTLs were more distal to transcription start sites, enriched in enhancers, less likely to regulate the nearest gene, and more than 3.5-fold more likely to colocalize with IBD loci detected in genome-wide association studies (GWASs) than eQTLs detected at tissue-level resolution. We nominate effector genes at more than half of known IBD loci, including MAML2 , PSEN2 and ZMIZ1 in myeloid cells, implicating reduced Notch signalling in intestinal immune dysfunction. We also identify Wnt-regulated genes, including MYC , in epithelial stem and progenitor cells, suggesting that impaired renewal contributes to barrier breakdown. Our results provide a mechanistic map that links genetic risk to specific genes and cell types in IBD, and a generalized framework for interpretation of GWAS loci using single-cell eQTL mapping of disease-relevant tissues in complex diseases.

25 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
TATobi Alegbe
Tobi Alegbe
BHBradley T Harris
Bradley T Harris
LFLaura Fachal
Laura Fachal
LRLucia Ramirez-Navarro
Lucia Ramirez-Navarro
MTMarcus Tutert
Marcus Tutert
CACarl A Anderson
Carl A Anderson
Most genetic variants associated with complex diseases lie in non-coding regions, complicating efforts to identify effector genes and relevant cell types. Here, we map cis-eQTLs across 2.2 million single cells from blood and intestinal biopsies of 421 individuals, including 125 with inflammatory bowel disease (IBD). Cell-type-level eQTLs were more distal to transcription start sites, enriched in enhancers, less likely to regulate the nearest gene, and over two-fold more likely to colocalise with IBD GWAS loci than eQTLs detected at tissue-level resolution. We nominate effector genes at over half of known IBD loci, including MAML2 , PSEN2, and ZMIZ1 in myeloid cells, implicating reduced Notch signalling in intestinal immune dysfunction. We also identify Wnt regulated genes, including MYC , in epithelial stem and progenitor cells, suggesting that impaired renewal contributes to barrier breakdown. Our results provide a mechanistic map linking genetic risk to specific genes and cell types in IBD, and a framework for effector gene discovery in complex disease.

27 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
OGOmar El Garwany
Omar El Garwany
NPNikolaos I. Panousis
Nikolaos I. Panousis
AKAndrew Knights
Andrew Knights
NKNatsuhiko Kumasaka
Natsuhiko Kumasaka
MIMaria Imaz
Maria Imaz
CACarl A. Anderson
Carl A. Anderson
The majority of immune-mediated disease (IMD) risk loci are located in non-coding regions of the genome, making it difficult to decipher their functional effects in relevant physiological contexts. To assess the extent to which alternative splicing contributes to IMD risk, we mapped genetic variants associated with alternative splicing (splicing quantitative trait loci or sQTL) in macrophages exposed to a wide range of environmental stimuli. We found that genes involved in innate immune response pathways undergo extensive differential splicing in response to stimulation and detected significant sQTL effects for over 5734 genes across all stimulation conditions. We colocalised sQTL signals for over 700 genes with IMD-associated risk loci from 22 IMDs with high confidence (PP4 ≥ 0.75). Approximately half of the colocalisations implicate lowly-used splice junctions (mean usage ratio <0.1). Finally, we demonstrate how an inflammatory bowel disease (IBD) risk allele increases the usage of a lowly-used isoform of PTPN2, a negative regulator of inflammation. Together, our findings highlight the role alternative splicing plays in IMD risk, and suggest that lowly-used splicing events significantly contribute to complex disease risk.

19 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
IFI. Ferreira
I. Ferreira
ORO. M. Rueda
O. M. Rueda
Louise van der WeydenLouise van der Weyden
Louise van der Weyden
SSS. Sahni
S. Sahni
OCO. Cast
O. Cast
DADavid Adams
David Adams
Sebaceous tumours (STs) are rare skin appendage tumours and include benign sebaceous adenoma (SA) and sebaceoma (SM), malignant extra-ocular sebaceous carcinoma (SC-E) and peri-ocular sebaceous carcinoma (SC-O). Here, an extensive worldwide collection of 286 tumours is deeply characterised, revealing a propensity to develop in the context of a high tumour mutational burden (except in SC-O) which is most frequently associated with mismatch repair deficiency (dMMR), followed by UV-induced damage, POLE/POLD1 mutations, and AID/APOBEC activation signatures. Biallelic TP53 inactivation with concomitant ZNF750 and/or RB1 mutation is seen in SC-E/SC-O. Amplification of 8q (including MYC ) is related to SC-O, while amplification of 1q21.3 (including HRNR ) and chromosome 20 are shared by SC-O and SC-E, as is deletion of 13q14.3 (where RB1 resides). The most frequently mutated gene is NOTCH1 . Extensive fusion gene, expression and molecular cluster analyses provide a molecular portrait of this rare and enigmatic tumour type.